Last reviewed · How we verify

NCT03639571

Phase I Study to Assess Irritation, Sensitization and Adhesion of a Novel Ibuprofen 200 mg TEPI Medicated Plaster

Completed Phase 1 Last updated 17 April 2019
What this trial tests

Phase 1 trial testing Ibuprofen 200 mg TEPI Medicated Plaster in Healthy in 33 participants. Completed in 25 October 2018.

Timeline
9 August 2018
Primary endpoint
25 October 2018
25 October 2018

Quick facts

Lead sponsorMedherant Ltd
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposetreatment
Enrollment33
Start date9 August 2018
Primary completion25 October 2018
Estimated completion25 October 2018
Sites1 location across Bulgaria

Drugs / interventions tested

Conditions studied

Sponsor

Medherant Ltd — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will be conducted with the aim to investigate the dermal response (skin irritation, sensitization) and the adhesion of Ibuprofen 200 mg TEPI Medicated Plaster as compared to a Placebo TEPI Plaster in two phases: Induction Phase: multiple dose application of one active and one placebo plaster on 5 consecutive days in which the plasters remain in place for 23 hours ± 30 min a day and Challenge Phase: single dose application of one active and one placebo plaster which remain in place for 48 hours ± 30 min.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ibuprofen 200 mg TEPI Medicated Plaster

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Medherant Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03639571.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing